Patents by Inventor Franziska Elena HERRMANN

Franziska Elena HERRMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240401057
    Abstract: Methods of treating and preventing fibrosis, and diseases/disorders characterised by fibrosis, through ADAMTS14 inhibition are disclosed, as well as agents for use in such methods.
    Type: Application
    Filed: October 7, 2022
    Publication date: December 5, 2024
    Applicants: Boehringer Ingelheim International GmbH, The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Franziska Elena Herrmann, Quang Huy Le, Peter Seither, Benjamin D. Medoff, Daniela Vanessa Moutinho Dos Santos, Yang Yang
  • Publication number: 20240142467
    Abstract: The PDE4-inhibitor of formula A? for use in a method for the treatment of a progressive fibrosing interstitial lung disease (PF-ILD), preferably IPF, in a patient comprising the following steps: a) measuring or having measured the concentration, expression level or activity of one or more biomarkers selected from the group consisting of Krebs von den Lungen protein (KL-6), Pulmonary Surfactant Protein D (SP-D), Matrilysin (MMP7), CA-125 (also named MUC-16), CA19-9, E-selectin, sICAM-1, Stromelysin (MMP3), osteopontin (OPN), connective tissue growth factor (CTGF), Cartilage oligomeric matrix protein (COMP), prostasin, von-Willebrand-Faktor (vWF), and C-reactive protein (CRP) in the serum or plasma of a blood sample obtained from said patient, b) comparing or having compared the concentration, expression level or activity of the one or more biomarkers as listed in step a) in said patient's blood serum or blood plasma sample to a reference concentration, expression level or activity of the respective one
    Type: Application
    Filed: September 26, 2023
    Publication date: May 2, 2024
    Inventors: Christian Benedikt Otto HESSLINGER, Franziska Elena HERRMANN, Yi LIU, Peter NICKOLAUS
  • Publication number: 20230405010
    Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 29, 2023
    Publication date: December 21, 2023
    Inventors: Franziska Elena HERRMANN, Peter NICKOLAUS, Stefan Ludwig Michael WOLLIN
  • Patent number: 11813266
    Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 12, 2022
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Franziska Elena Herrmann, Peter Nickolaus, Stefan Ludwig Michael Wollin
  • Publication number: 20220378793
    Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 12, 2022
    Publication date: December 1, 2022
    Inventors: Franziska Elena HERRMANN, Peter NICKOLAUS, Stefan Ludwig Michael WOLLIN
  • Patent number: 11406638
    Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitor of formula III or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 9, 2022
    Assignee: Boehringer Ingelheim Internatinal GmbH
    Inventors: Franziska Elena Herrmann, Peter Nickolaus, Stefan Ludwig Michael Wollin
  • Publication number: 20190134043
    Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitor of formula III or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 22, 2018
    Publication date: May 9, 2019
    Inventors: Franziska Elena HERRMANN, Peter NICKOLAUS, Stefan Ludwig Michael WOLLIN